<DOC>
	<DOCNO>NCT00263666</DOCNO>
	<brief_summary>The aim study evaluate reactogenicity , safety immunogenicity GSK Biologicals ' human rotavirus ( HRV ) vaccine give concomitantly routine vaccine include OPV HIV positive infant . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>A Study Safety , Reactogenicity Immunogenicity HRV Vaccine HIV Infected Infants South Africa</brief_title>
	<detailed_description>HIV infect infant determine prior study entry ( screen ) asymptomatic mildly symptomatic ( WHO stag I II ) disease enrol . The study two group : Group HRV Group Placebo . Three-dose immunisation administer approximately 6 , 10 , 14 week age . Routine EPI ( Expanded Program Immunisation ) vaccination administer concomitantly study vaccine . At time first dose , subject age 6 10 week . This study evaluate safety , reactogenicity immunogenicity HRV vaccine relative placebo .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include 6 10 week age time first vaccination . Written inform consent obtain parent guardian subject Documented HIV status subject confirm PCR . HIV asymptomatic HIV mildly symptomatic ; Stages I II disease accord WHO 's recent classification HIV stag infant child . Born gestation period 36 42 week . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Previous routine vaccination except OPV , BCG HBV vaccination birth Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract serious medical condition determine investigator . History allergic disease reaction likely exacerbated component vaccine . Acute disease time enrolment . Gastroenteritis within 7 day precede study vaccine administration . Previous confirm occurrence RV gastroenteritis . Other condition opinion investigator may potentially interfere interpretation study outcome . HIV moderately severely symptomatic : stage III IV accord WHO 's recent classification . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>